CSL Shares Slump as Disappointing Profit Eclipses Spinoff

CSL Ltd. shares plunged the most in almost 17 years after the Australian biotech giant reported disappointing earnings, overshadowing a restructuring plan that will see it spin off its Seqirus vaccine business and cut costs by around $500 million a year.